Related coverage linked through entity extraction aliases.
Aug 08, 2026
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
Jun 26, 2026
Studies reveal context-dependent genetic effects in psychiatric disorders, reassuring evidence on prenatal antidepressant use, and findings on parental depression timing, diagnostic interview reliability, and rising self-diagnosis.
Apr 28, 2026
The Trump administration is reclassifying medical marijuana from Schedule I to Schedule III and accelerating psychedelic research with a $50 million executive order. The FDA commissioner says marijuana has medical benefits but warns of potency and risks to youth. The DEA says the rescheduling process remains pending.
Jun 27, 2026
ACADIA Pharmaceuticals' stock jumped after the European Medicines Agency recommended approval of its Rett syndrome drug Daybue. The company also reported strong quarterly results and progress on its Alzheimer's disease psychosis treatment.
Jun 25, 2026
MRI-guided brain stimulation achieved 80% response rates for treatment-resistant depression versus 60% with conventional targeting, per a JAMA Psychiatry study. Separately, Barcelona researchers developed an MRI tool to accurately identify rare neurodegenerative tauopathies PSP and CBD, while experts in Paris discussed AI's growing role in predictive psychiatry.
May 13, 2026
Drug-soaked paper has become the most commonly found drug in Ohio prisons and was tied to at least 13 fatal K2 overdoses in 2024. Convictions in the state’s largest prison drug conspiracy case detailed how the paper was smuggled and sold.
Apr 24, 2026
A longitudinal study of 460,000 teenagers found adolescent cannabis use was linked to higher risks of later bipolar, psychotic, anxiety and depression diagnoses. Separate research and expert guidance say THC effects, especially long term, still need more study.
Apr 13, 2026
Neurocrine Biosciences initiated and dosed the first patients in a Phase 2 trial of NBI-1117570 in adults with schizophrenia. Nxera Pharma said it will receive US$22.5 million in milestone payments to be recognised as Q1 FY2026 revenue.
Mar 26, 2026
Research reveals how ectopic NMDA receptor expression in triple-negative breast cancer triggers autoimmune disease through antibody maturation. The study shows NMDAR expression recruits B cells and drives affinity maturation, producing antibodies that can cross the blood-brain barrier and cause neurological symptoms while constraining tumor growth.
Mar 18, 2026
A longitudinal study of 460,000 teenagers found that adolescent cannabis use increases the risk of developing bipolar and psychotic disorders by twofold, as well as raising risks for depression and anxiety.
Feb 16, 2026
A phase IIa clinical trial found that a single intravenous dose of dimethyltryptamine (DMT) with psychological support rapidly reduced depressive symptoms in 34 adults with major depressive disorder, with improvements sustained for up to three months.
Feb 16, 2026
Researchers identified shared white matter alterations in the corpus callosum as a common biomarker across schizophrenia and bipolar disorder, supporting the concept of a psychosis spectrum rather than distinct disorders.
